WorldCat Identities

Padró, Teresa

Overview
Works: 9 works in 9 publications in 1 language and 16 library holdings
Roles: Other, Contributor
Publication Timeline
.
Most widely held works by Teresa Padró
Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Relation of Urokinase-Type Plasminogen Activator Expression to Presence and Severity of Atherosclerotic Lesions in Human Coronary Arteries( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Protective mechanisms of adenosine 5′-monophosphate in platelet activation and thrombus formation( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

High-molecular-weight kininogen and the intrinsic coagulation pathway in patients with de novo acute myocardial infarction( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers( )

1 edition published in 2014 in English and held by 1 WorldCat member library worldwide

Drug-induced vascular injury (DIVI) is a common preclinical toxicity usually characterized by hemorrhage, vascular endothelial and smooth muscle damage, and inflammation. DIVI findings can cause delays or termination of drug candidates due to low safety margins. The situation is complicated by the absence of sensitive, noninvasive biomarkers for monitoring vascular injury and the uncertain relevance to humans. The Safer And Faster Evidence-based Translation (SAFE-T) consortium is a public-private partnership funded within the European Commission's Innovative Medicines Initiative (IMI) aiming to accelerate drug development by qualifying biomarkers for drug-induced organ injuries, including DIVI. The group is using patients with vascular diseases that have key histomorphologic features (endothelial damage, smooth muscle damage, and inflammation) in common with those observed in DIVI, and has selected candidate biomarkers associated with these features. Studied populations include healthy volunteers, patients with spontaneous vasculitides and other vascular disorders. Initial results from studies with healthy volunteers and patients with vasculitides show that a panel of biomarkers can successfully discriminate the population groups. The SAFE-T group plans to seek endorsement from health authorities (European Medicines Agency and Food and Drug Administration) to qualify the biomarkers for use in regulatory decision-making processes
 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.96 (from 0.88 for Relation o ... to 0.97 for Relation o ...)

WorldCat IdentitiesRelated Identities
Languages